According to market projections, the HLA testing market is expected to grow from US$930.91 million in 2025 to US$1,780.10 million by 2034, representing a compound annual growth rate (CAGR) of 7.47% from 2026 to 2034. This robust growth highlights the expanding role of immunogenetics in modern healthcare, particularly in transplantation, autoimmune disease diagnosis, and pharmacogenomics research. 

The Global Human Leukocyte Antigen (HLA) Testing Market is on a strong upward trajectory, and the numbers tell a compelling story. The HLA Testing market size is expected to reach US$1,780.10 million by 2034 from US$930.91 million in 2025, registering a CAGR of 7.47% during the forecast period from 2026 to 2034. This growth reflects a broader shift in how modern medicine approaches transplantation, autoimmune diagnostics, and precision pharmacology.

What Is HLA Testing and Why Does It Matter?

HLA testing is a critical diagnostic procedure that determines compatibility between a donor and recipient for organ, tissue, and hematopoietic stem-cell transplantation. HLA proteins, located on the surface of most cells, regulate the immune system, and their accurate matching is essential to minimize transplant rejection and improve long-term graft survival. Beyond transplantation, HLA testing is increasingly applied in diagnosing conditions like celiac disease and rheumatoid arthritis, as well as in pharmacogenomics to assess how patients respond to specific medications.

Get Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00021578

Key Growth Drivers

Three primary forces are accelerating market expansion. First, the rise of high-resolution molecular diagnostics is transforming the field. The strategic shift from low-resolution serological methods to high-resolution molecular techniques, especially Next-Generation Sequencing (NGS), is driving market value, as NGS offers superior specificity, faster turnaround times, and the ability to detect novel alleles.

Second, growing clinical evidence linking specific HLA alleles to autoimmune conditions like Type 1 diabetes and ankylosing spondylitis is increasing the utilization of HLA typing for diagnostic confirmation and risk stratification.

Third, pharmacogenomics applications are broadening market scope. HLA testing is crucial for predicting adverse drug reactions, such as drug hypersensitivity syndrome associated with certain HIV or anti-epileptic drugs, expanding its role well beyond the traditional transplant setting.

Market Segmentation Snapshot

The market structure is heavily skewed toward Reagents and Consumables, which account for over 70% of total revenue due to the repetitive nature of testing and high throughput volumes in reference laboratories and transplant centers. Technology-wise, molecular assay methods dominate, while end users range from independent reference laboratories to hospitals and transplant centers.

Regional Highlights

North America holds the largest market share due to high transplant procedure volumes, early adoption of advanced molecular assays, and well-established diagnostic reimbursement policies. Meanwhile, Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by rapid digitalization of healthcare, government support for organ donation programs in China and India, and rising healthcare expenditure.

Emerging Opportunities

The demand for AI-driven data analytics and automated laboratory workflows is creating opportunities to develop integrated software solutions that can quickly interpret complex HLA data, reduce human error, and streamline reporting for clinicians. Additionally, emerging single-cell HLA transcript analysis technologies promise enhanced allele specificity for precision diagnostics.

Competitive Landscape

Key players shaping this market include Thermo Fisher Scientific, CareDx, Qiagen, Illumina, Bio-Rad Laboratories, and F. Hoffmann-La Roche. Illumina supports the TruSight HLA v2 Sequencing Panel with enhanced software that improves structural variant detection by approximately 30%, while also announcing DRAGEN v4.4 pipeline support for two-field resolution HLA genotyping.

Conclusion

The HLA Testing market is evolving from a niche transplant tool into a cornerstone of precision diagnostics. With NGS adoption accelerating, AI integration expanding, and emerging markets coming online, stakeholders across pharma, diagnostics, and healthcare have significant opportunities to capture value in this fast-growing sector through 2034.

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:
If you have any queries about this report or if you would like further information, please get in touch with us:
Website: https://www.theinsightpartners.com/
Phone: +1-646-491-9876